Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab

EVALUATION CLINIQUE ET BIOLOGIQUE A LONG TERME DES PATIENTS ATTEINTS DE FORMES SEVERES DE PEMPHIGUS TRAITES PAR LE RITUXIMAB

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01299857

Acronym

Suiviritux

Enrollment

Registered

2011-02-18

Start date

2011-06-30

Completion date

2012-06-30

Last updated

2012-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pemphigus

Keywords

pemphigus, Mabthéra (R), B lymphocytes, desmogleines

Brief summary

The purpose of this study is to study the midterm clinical evaluation, biological parameters and immune reconstitution after Rituximab treatment for Pemphigus.

Interventions

DRUGRituximab

375mg/m2

Study design

Allocation

Intervention model

SINGLE_GROUP

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* age\>18 * consentment * patient treated with Rituximab and included in clinical trial n°2002/020/HP - NCT00213512 Treatment of Patients Presenting Pemphigus With Anti CD20 (Mabthera).

Exclusion criteria

* age \< 18 * no consentment

Design outcomes

Primary

Measure	Time frame	Description
Rate of relapse after 5 years of treatment	five years	Primary outcome measure is the evaluation of Rate of relapse after 5 years of treatment by rituximab for patient with pemphigus. The relapse is defined by the reappearance of mucous or cutaneous érosives lésions proved by histology and by direct immunofluorescence

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026